Serosurvey in BNT162b2 vaccine-elicited neutralizing antibodies against authentic B.1, B.1.1.7, B.1.351, B.1.525 and P.1 SARS-CoV-2 variants.
BNT162b2 vaccine
SARS-CoV-2
neutralizing antibodies
variant of concern
variant of interest
Journal
Emerging microbes & infections
ISSN: 2222-1751
Titre abrégé: Emerg Microbes Infect
Pays: United States
ID NLM: 101594885
Informations de publication
Date de publication:
Dec 2021
Dec 2021
Historique:
pubmed:
8
6
2021
medline:
24
6
2021
entrez:
7
6
2021
Statut:
ppublish
Résumé
In this study, we show that BNT162b2 vaccine-elicited antibodies efficiently neutralize SARS-CoV-2 authentic viruses belonging to B.1, B.1.1.7, B.1.351, B.1.525 and P.1 lineages. Interestingly, the neutralization of B.1.1.7 and B.1.525 lineages was significantly higher, whereas the neutralization of B.1.351 and P.1 lineages was robust but significantly lower as compared to B.1 lineage. Following our findings, we consider that the BNT162b2 vaccine offers protection against the current prevailing variants of SARS-CoV-2.
Identifiants
pubmed: 34092181
doi: 10.1080/22221751.2021.1940305
pmc: PMC8216260
doi:
Substances chimiques
Antibodies, Neutralizing
0
Antibodies, Viral
0
COVID-19 Vaccines
0
BNT162 Vaccine
N38TVC63NU
Types de publication
Letter
Langues
eng
Sous-ensembles de citation
IM
Pagination
1241-1243Références
Cell. 2020 Sep 3;182(5):1295-1310.e20
pubmed: 32841599
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
Cell. 2021 Apr 1;184(7):1821-1835.e16
pubmed: 33667349
N Engl J Med. 2021 Mar 8;384(15):1466-1468
pubmed: 33684280